Published in J Immunol on January 01, 1982
Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A (1985) 1.16
Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J Immunol (2011) 0.96
Mapping of the properdin-binding site in the third component of complement. Biochem J (1984) 0.89
Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3b. J Mol Biol (2010) 0.88
Crystallization of human complement component C3b in the presence of a staphylococcal complement-inhibitor protein (SCIN). Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.88
Opsonized streptococcal cell walls cross-link human leukocytes and erythrocytes by complement receptors. Infect Immun (1985) 0.80
Inhibition of neutrophil function by fluid phase C3b of complement. Infect Immun (1983) 0.75
Inhibition of the alternative pathway of complement by glomerular chondroitin sulphate proteoglycan. Immunology (1992) 0.75
Combined studies of complement receptor and surface immunoglobulin-bearing cells and sheep erythrocyte rosette-forming cells in normal and leukemic human lymphocytes. J Clin Invest (1973) 5.31
Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b. J Exp Med (1973) 4.46
Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol (1997) 3.05
Herpes simplex virus glycoprotein D can bind to poliovirus receptor-related protein 1 or herpesvirus entry mediator, two structurally unrelated mediators of virus entry. J Virol (1998) 3.00
Expression of Ia-like antigen molecules on human granulocytes during early phases of differentiation. Proc Natl Acad Sci U S A (1977) 2.80
Membrane complement receptors specific for bound fragments of C3. Adv Immunol (1985) 2.80
Specificity of human lymphocyte complement receptors. J Exp Med (1975) 2.77
Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies. J Immunol (1981) 2.74
Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev (2001) 2.69
Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol (1982) 2.68
Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol (1996) 2.41
Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. J Exp Med (1982) 2.36
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
Analysis of the different types of leukocyte membrane complement receptors and their interaction with the complement system. J Immunol Methods (1980) 2.17
p150/95, Third member of the LFA-1/CR3 polypeptide family identified by anti-Leu M5 monoclonal antibody. Eur J Immunol (1985) 2.14
Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin. J Exp Med (1980) 1.96
Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Invest (1988) 1.92
Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol (1996) 1.86
Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibody. Proc Natl Acad Sci U S A (1981) 1.86
Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol (1994) 1.81
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol (2001) 1.73
Membrane receptors of mouse leukocytes. II. Sequential expression of membrane receptors and phagocytic capacity during leukocyte differentiation. J Exp Med (1978) 1.69
Dissociation between increased surface expression of gp165/95 and homotypic neutrophil aggregation. J Immunol (1988) 1.56
The sequential appearance of Ia-like antigens and two different complement receptors during the maturation of human neutrophils. J Exp Med (1978) 1.56
Structural and antigenic analysis of a truncated form of the herpes simplex virus glycoprotein gH-gL complex. J Virol (1998) 1.54
Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J Immunol (1998) 1.49
Complement and innate immunity. Immunopharmacology (2000) 1.48
In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J Exp Med (1999) 1.46
Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochem J (1984) 1.44
Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol (2000) 1.44
Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci U S A (1999) 1.42
Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol Cell Probes (1987) 1.37
Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J Virol (1996) 1.36
Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 1.35
The multifunctional role of C3, the third component of complement. Immunol Today (1988) 1.32
Human megakaryocytes. I. Characterization of the membrane and cytoplasmic components of isolated marrow megakaryocytes. J Exp Med (1979) 1.31
Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J Immunol (1994) 1.30
Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol (1998) 1.26
Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. J Immunol (1993) 1.26
Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost (2008) 1.26
Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology (2000) 1.24
Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem J (1985) 1.24
Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J Immunol (1997) 1.22
Structural aspects and design of low-molecular-mass complement inhibitors. Biochem Soc Trans (2002) 1.22
Identification of human lymphocyte subpopulations by surface marker analysis. Blood (1979) 1.22
Localization of the conglutinin binding site on the third component of human complement. J Immunol (1985) 1.21
Characterization of the lymphocyte membrane receptor for factor H (beta 1H-globulin) with an antibody to anti-factor H idiotype. J Exp Med (1982) 1.21
The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A (2008) 1.20
Disulfide bond structure determination and biochemical analysis of glycoprotein C from herpes simplex virus. J Virol (1996) 1.19
Assay for the two different types of lymphocyte complement receptors. Scand J Immunol (1976) 1.18
Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells. Leukemia (2004) 1.17
Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A (1985) 1.16
Infection of human thymocytes by Epstein-Barr virus. J Exp Med (1991) 1.15
Solution structure of Compstatin, a potent complement inhibitor. Protein Sci (1998) 1.15
Structure and function of membrane complement receptors. Summary. Fed Proc (1982) 1.15
Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. J Immunol (1990) 1.14
Surface markers of human eosinophils. Blood (1976) 1.13
Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220. J Immunol (2001) 1.12
Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan. Immunopharmacology (2000) 1.12
Use of monoclonal antibodies against factor H to investigate the role of a membrane-associated protein antigenically related to H in C3b-receptor function. J Immunol (1984) 1.12
Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood (1998) 1.11
Comparison of various tests for Fc receptors on different human lymphocyte sub populations. Clin Exp Immunol (1979) 1.10
The three HveA receptor ligands, gD, LT-alpha and LIGHT bind to distinct sites on HveA. Mol Immunol (2000) 1.10
Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol (1999) 1.09
Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d. J Immunol (1983) 1.09
Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule. EMBO J (1989) 1.08
Expression of the third component of complement, C3, in regenerating limb blastema cells of urodeles. J Immunol (1998) 1.07
The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway. Virology (1994) 1.06
Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin Immunol (2000) 1.06
Expression of EBV/C3d receptors on T cells: biological significance. Immunol Today (1993) 1.05
gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4). Eur J Immunol (1985) 1.05
Role of complement receptor type three and serum opsonins in the neutrophil response to yeast. Complement (1987) 1.05
Accumulation of viruslike particles in a yeast mutant lacking a mitochondrial pore protein. Mol Cell Biol (1989) 1.04
Staurosporine inhibits neutrophil phagocytosis but not iC3b binding mediated by CR3 (CD11b/CD18). J Immunol (1991) 1.04
Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur J Immunol (1988) 1.03
Interaction of platelet membrane receptors with von Willebrand factor, ristocetin, and the Fc region of immunoglobulin G. J Clin Invest (1978) 1.03
Surface markers of complement receptor lymphocytes. J Clin Invest (1978) 1.03
Sea urchin coelomocytes specifically express a homologue of the complement component C3. J Immunol (1998) 1.02
Structural analysis of the asparagine-linked oligosaccharides of human complement component C3. Biochem J (1986) 1.01
Generation of recombinant fragments of CD11b expressing the functional beta-glucan-binding lectin site of CR3 (CD11b/CD18). J Immunol (1999) 1.01
Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J Clin Invest (1985) 1.01
Structural and functional analysis of C3 using monoclonal antibodies. Curr Top Microbiol Immunol (1990) 1.01
Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. Biochemistry (2001) 1.00
Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1. J Immunol (2000) 1.00